eligibility_summary
Adults ≥18 with relapsed/refractory multiple myeloma per IMWG, BCMA+ (>5%) on marrow, measurable disease (serum M ≥1 g/dL, urine M ≥200 mg/24h, or FLC ≥10 mg/dL with abnormal ratio), ECOG 0–1, ≥1 prior line. Exclude: plasma cell leukemia/WM/POEMS/amyloidosis, prior CAR‑T/BCMA, ASCT <12 wks or any allo‑SCT, immunodeficiency/HIV, active HBV/HCV, unable to take PJP/HSV/VZV prophylaxis or syphilis+, TB in 2 yrs, ILD/severe lung disease, active infection, severe CV disease.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: SYS6020, a BCMA-targeted CAR T-cell therapy (gene-modified autologous T cells) given by IV infusion with dose escalation. Mechanism: Patient T cells are engineered ex vivo to express a chimeric receptor that binds B-cell maturation antigen (BCMA), engagement triggers CAR signaling, activating T-cell cytotoxicity and cytokine release to selectively eliminate BCMA-expressing cells. Targets: BCMA (TNFRSF17) on malignant plasma cells (and normal plasma cells) in multiple myeloma, activates T-cell effector pathways (immune synapse, perforin/granzyme-mediated lysis) to eradicate BCMA+ myeloma. Indication: Relapsed/refractory BCMA-positive multiple myeloma.